- Home
- PROK vs BLFY Comparison
PROK vs BLFY Comparison
Compare PROK & BLFY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PROK
- BLFY
- Stock Information
- Founded
- PROK 2015
- BLFY 1939
- Country
- PROK United States
- BLFY United States
- Employees
- PROK N/A
- BLFY N/A
- Industry
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- BLFY Commercial Banks
- Sector
- PROK Health Care
- BLFY Finance
- Exchange
- PROK Nasdaq
- BLFY Nasdaq
- Market Cap
- PROK 220.6M
- BLFY 254.5M
- IPO Year
- PROK N/A
- BLFY N/A
- Fundamental
- Price
- PROK $1.70
- BLFY $11.24
- Analyst Decision
- PROK Buy
- BLFY Hold
- Analyst Count
- PROK 5
- BLFY 2
- Target Price
- PROK $4.50
- BLFY $10.63
- AVG Volume (30 Days)
- PROK 437.3K
- BLFY 65.4K
- Earning Date
- PROK 11-12-2024
- BLFY 10-23-2024
- Dividend Yield
- PROK N/A
- BLFY N/A
- EPS Growth
- PROK N/A
- BLFY N/A
- EPS
- PROK N/A
- BLFY N/A
- Revenue
- PROK N/A
- BLFY $40,112,000.00
- Revenue This Year
- PROK N/A
- BLFY N/A
- Revenue Next Year
- PROK N/A
- BLFY $16.37
- P/E Ratio
- PROK N/A
- BLFY N/A
- Revenue Growth
- PROK N/A
- BLFY N/A
- 52 Week Low
- PROK $1.12
- BLFY $7.90
- 52 Week High
- PROK $4.44
- BLFY $11.48
- Technical
- Relative Strength Index (RSI)
- PROK 43.50
- BLFY 65.61
- Support Level
- PROK $1.95
- BLFY $10.79
- Resistance Level
- PROK $2.27
- BLFY $11.38
- Average True Range (ATR)
- PROK 0.18
- BLFY 0.28
- MACD
- PROK 0.03
- BLFY 0.12
- Stochastic Oscillator
- PROK 26.45
- BLFY 90.97
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of development program for severe diabetic kidney disease.
About BLFY Blue Foundry Bancorp
Blue Foundry Bancorp is a full-service bank. Its business consists of originating one-to-four-family residential, multi-family, and non-residential real estate mortgages, home equity loans and lines of credit, and commercial and industrial loans. It attracts retail deposits from the general public in the areas surrounding its banking offices, through its borrowers, and through its online presence, offering a wide variety of deposit products. The bank also invests in securities. Its revenues are derived from interest on loans and, to a lesser extent, interest on mortgage-backed and other investment securities. The company's sources of funds are deposits, principal, and interest payments on loans, securities, and borrowings from the Federal Home Loan Bank of New York.